Biohaven Pharma (BHVN) Misses Q4 EPS by 11c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• BMO Capital Upgrades Incyte (INCY) to Market Perform
• Instacart (CART) Reiterated at Market Outperform by Citizens amid AI Assistant Rollout